Know Cancer

or
forgot password

Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction


N/A
18 Years
70 Years
Open (Enrolling)
Both
Malignant Biliary Obstruction

Thank you

Trial Information

Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction


We will obtain bile sample for culture and susceptibility ,proteomics metabonomics test
after PTBD. Also get the blood and urine samples.


Inclusion Criteria:



- Those with MBO who can receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Exclusion Criteria:

- Those with MBO who cannot receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Principal Investigator

YU HAI PENG, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Tianjin Medical University Cancer Institute and Hospital

Authority:

China: Food and Drug Administration

Study ID:

TMU-CIH-IR-001

NCT ID:

NCT01073514

Start Date:

December 2009

Completion Date:

December 2013

Related Keywords:

  • Malignant Biliary Obstruction
  • Malignant biliary obstruction (MBO)

Name

Location